Introduction
The bone marrow continuously generates enormous numbers of B cells, each equipped with a unique surface immunoglobulin (Ig) antigen receptor. This is possible by an ordered sequence of somatic recombination events that result in random rearrangements of the Ig heavy chain (IgH) and light chain (IgL) loci. This process of V(D)J recombination commences in pro-B cells with D to J rearrangements of the IgH loci [1] . A productive IgH rearrangement results in surface M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 3 expression of the pre-B cell receptor (BCR) complex composed of a functional heavy chain and a surrogate light chain [2] . Antigen-independent, "tonic" signaling by this complex triggers a number of rapid cell divisions but subsequently also provides antiproliferative and maturation signals [3] . V(D)J recombination of T cell receptor loci and T cell development in the thymus follow similar principles [4] .
Malignant growth of a precursor B cell clone causes B cell acute lymphoblastic leukemia (B-ALL), the most common malignant disease in childhood [5] . In 20% of ALL cases, the malignant clone originates from precursor T cells. B-ALL is genetically heterogeneous and can be grouped according to the presence of several characteristic oncogenic mutations or translocations [6] . A common theme, however, is that B-ALL clones are arrested at the pre-B cell checkpoint, hi-jack pre-BCR signaling for their survival but at the same time evade the anti-proliferative and differentiation cues from physiological pre-BCR signaling [7] . In a fraction of B-ALL patients, the malignant clone depends on tonic signaling from a functional pre-BCR for its survival .
The tyrosine kinase KIT, the receptor for the hematopoietic growth factor stem cell factor (SCF) is expressed by hematopoietic stem cells as well as all progenitor cells [8] . While more mature cells of all lineages gradually shut down KIT expression, mast cells remain dependent on KIT signaling for their entire life-span. KIT activation triggers several signaling pathways, including phosphoinositol 3-kinases (PI3K), Src family kinases and the mitogen-activated-protein-kinase (MAPK), janus kinase/signal transducers and activators of transcription (JAK/STAT) and phospholipase C and D signaling [9] . Gain-of-function mutations of KIT that result in constitutive, ligandindependent signaling cause the human disease mastocytosis [10] . This condition is hematological non-mast cell lineage disease (AHNMD), typically myeloproliferative, myelodysplastic syndromes or myeloid leukemias [10] .
We recently generated a transgenic mouse model for mastocytosis [11] . These animals conditionally express the Kit D814V mutation, which is the murine homolog of the most common mastocytosis-associated mutation in humans, KIT D816V . Transgenic expression of the mutant protein is controlled by the Kit promoter. Effects of the constitutively active Kit transgene were dependent on developmental stage and cell type. Widespread expression in the embryo resulted in lethal erythroid hyperproliferation, while induction of transgene expression in adult mice led to massive mastocytosis. This latter condition was associated with an additional hematopoietic neoplasm in about half of the animals, which rapidly succumbed to this disease. These mice featured lymphadenopathy, an abnormal population of CD19 + B220 + cells in the blood, and infiltration of various organs by blastic B cells.
These findings suggested that uncontrolled Kit activity causes B cell leukemia in mice. Herein, we pinpoint the origin of this B cell malignancy.
In some animals, Mx1-Cre was induced by a total of three i.p. injections of 250 µg poly-inosinic:poly-cytidilic acid (pI:pC, Invivogen, Toulouse, France) every second day. Uninduced Kit D814Vflox Mx1-Cre mice developed similar phenotypes due to background recombination of Mx1-Cre [11] .
Southern blotting
Genomic DNA was isolated from enlarged lymph nodes of leukemic mice, 10 
Flow cytometry
Cells were incubated with monoclonal antibodies (see supporting information table 1 for detailed overview) for 30 minutes in PBS/5% FCS, washed twice and analyzed on FACS LSRII or FACS Calibur (Becton Dickinson). Data analysis was performed using FlowJo V9 software (Treestar).
For transplantation of purified cell populations, cells were sorted on a BD FACS ARIAII, mixed with 200,000 BM "carrier" cells of recipient origin and retro-orbitally i.v.
injected.
For analysis of intracellular phosphoprotein expression, cells were fixed using IC fixation buffer (eBioscience) and methanol followed by incubation with phosphospecific antibodies (see supplementary table 1) and analysis on a BD FACS Calibur flow cytometer.
Statistics
Kaplan-Meier survival curves were plotted using Prism 5 (Graphpad). Significance between survival curves was calculated using the Log-rank test ( Fig 3A, 4A, 7C and S3D). Two-sided Student´s t-test was used for group comparison (Fig 6C and S1B ). 
Results

Immuno-phenotype of neoplastic B cells from leukemic Kit D814V
transgenic mice resembles pro-B cells. was frequently lethal within few days after first clinical manifestation [11] . Flow cytometric analysis of peripheral blood (PB) and spleen from diseased Kit D814Vflox+
Mx1-Cre + mice revealed an abnormal population of B220 intermediate (B220 int ) BP-1 high (BP-1 hi ) cells ( Fig 1A) , which were negative for surface IgM (Fig S1A) . Many animals featured macroscopically enlarged lymph nodes, which represented an essentially pure population of the B220 int BP-1 hi cells ( Fig 1A) . Fig S1B) . BM B220 + cells from leukemic mice were negative for IgM and IgD and uniformly over-expressed CD19 and BP-1, while CD34, CD135, CD21/35 and CD79b were not detected and only few cells expressed CD25 and Sca-1 ( Fig 1B and S1C) . B220, CD24, CD43, CD93 and CD127 expression levels of the abnormal cells were similar to those of control precursor B cells (B220 int CD43 hi ) [15] .
Taken together, the malignant B220 + cells immuno-phenotypically resembled Hardy fraction B or C pro-B cells of the "Philadelphia nomenclature" [1] , a population that overlaps with pre-B-I cells of the "Basel nomenclature" [16] (see Fig S4 for an overview).
Neoplastic B lineage clones carry rearranged IgH but mostly germ line
configured Igκ κ κ κ loci.
In order to further narrow down the differentiation state of the neoplasia, we analyzed the configuration of the IgH and Igκ loci in DNA isolated from enlarged lymph nodes of leukemic animals. Southern blot analysis revealed one or two non-germline bands in all cases (Fig 2A) , providing formal proof that the B220 int BP-1 hi cells represent a clonal population of D-J H rearranged B lineage cells (the probe used did not discriminate between D-J H and V-DJ H rearrangements). Germline bands occurred in most samples and were either caused by mono-allelic recombination or stroma cells.
In contrast, the Igκ locus was germline-configured in eight of nine cases analyzed ( Fig 2B) . This clearly demonstrates that most leukemias originated from cells that had undergone heavy chain, but not light chain rearrangement.
Malignant transformation of precursor B cells in Kit D814V transgenic mice
is independent of pre-B cell receptor signals.
Analysis of Ig gene rearrangements and immuno-phenotype of neoplastic cells
revealed their similarity to pro-B cells. During normal B cell development, surface expression of a functional pre-BCR triggers a proliferative burst of pre-B cells [17, 18] , but also mediates anti-proliferative and maturation signals [7] . We hypothesized that pre-BCR expression critically impacts malignant transformation of Kit D814V B cell progenitors, and crossed Kit D814Vflox Mx1-Cre mice to the IgH µMT strain, that is incapable of expressing a functional pre-BCR [12] . In IgH µMT animals, B cell development is blocked in Hardy fraction C [15, 19] , which overlaps with pre-B-I cells [20] . The incidence of lethal B lineage neoplasia was not significantly altered in 
Selective expression of Kit D814V in CD19 + B cell precursors is sufficient to trigger malignant transformation.
In order to restrict Kit D814V expression to B-lineage committed progenitors, we crossed the Kit D814Vflox allele to CD19-Cre mice [13] . In the latter, Cre-mediated recombination initiates after pre-pro-B cells (Hardy fraction A [15] ) and is efficient in fraction B pro-B cells [21] [22] [23] . The majority of Kit D814Vflox+ CD19-Cre + mice (9 of 12 Fig 4A) died spontaneously or was sacrificed for end stage disease between 9 to 17 weeks of age. All animals analyzed by flow cytometry (7/9) exhibited strong infiltration of the BM with B220 + BP-1 hi cells ( Fig 4B) . Similar to the disease in 
High frequency of leukemia initiating cells.
In order to determine the frequency of leukemia initiating cells [24] within the malignant clone, we purified B220 int BP-1 hi CD117 + cells from a diseased Kit D814Vflox+
Mx1-Cre + donor by flow cytometry and injected cell numbers ranging from 10 1 to 5 x 10 4 cells into un-conditioned congenic B6.CD45.1 recipients ( Fig 5A) . We monitored recipient PB for appearance of donor-derived (CD45.2 + ) B220 int BP-1 hi cells ( Fig 5B) and found dose dependent engraftment and expansion of donor cells. All mice developed end stage disease between 19 to 34 days after transfer. Only two of the three recipients, which received ten leukemic precursor-B cells survived without detectable engraftment of donor cells in PB and BM and did not develop leukemia within 137 days after transfer. The frequency of leukemia initiating cells was determined to be about 1 in 20 leukemic cells ( Fig 5C) .
Derivation of pro-B cell lines.
We cultivated leukemic cells from the BM of the diseased Kit D814Vflox+ Mx1-Cre + animal represented in Fig S2A. The cultivated cells maintained B220 and BP-1 expression ( Fig 6A) and rapidly proliferated in serum-containing media ( Fig 6B) . We investigated the malignant potential of the cell line (termed "RW7938") by i.v.
injection of 10 6 cells into congenic B6.CD45.1 mice (n=3, Fig 6C) . All recipients appeared moribund 14 days after transfer and were sacrificed. We determined the frequency of donor-derived CD45.2 + BP-1 hi cells among BM cells ( Fig 6C) and found strong BM infiltration and expansion of donor pro-B cells. We similarly cultivated a cell line ("AG11232") from a diseased Kit D814Vflox+ CD19-Cre + animal that rapidly grew in culture and was transplantable ( Fig S3) Next, we compared the phosphorylation of intracellular signaling proteins of Kit D814V pro-B cell lines to primary lymphocytes and found constitutive phosphorylation of ERK1/2, mTOR, STAT3/5 and AKT pathways ( Fig 6E, S2C and S3E ). This constitutive activation could be blocked by nanomolar concentrations of the tyrosine kinase inhibitors PKC412 and Dasatinib ( Fig 6D, S2B and S3F), which have been shown to target the Kit D814V mutation [25, 26] . Imatinib did not block phosphorylation of Kit D814V target proteins and inhibited cell growth only at high micromolar concentrations ( Fig S2B,C and S3E ,F). The decreased growth rate of Rapamycintreated pro-B cell lines showed that constitutive activation of the mTOR signaling pathway contributes to aberrant growth of these cell lines.
Rare occurrence of pre-T cell leukemia in Kit D814Vflox Mx1-Cre mice.
Less than 5% of Kit D814Vflox+ Mx1-Cre + mice developed large thymi ( Fig 7A) . These animals featured an abnormal population of CD4/8 double positive cells in PB and spleen ( Fig 7B) . Thymus analysis revealed a massive increase of CD4/CD8 double showed strong upregulation of CD25 and moderate upregulation of CD117 ( Fig 7B) and CD44 (not shown) in comparison to control DP thymocytes. The CD4/8 double negative (DN) thymocytes displayed an aberrant CD44 + and CD25 lo phenotype.
Upon transfer of different numbers of total thymic cells from a diseased Kit D814Vflox+
Mx1-Cre + animal, congenic recipient mice In recipients that received 1 x 10 6 donor thymocytes, high numbers of CD4/8 DP cells of donor origin appeared in PB 13 days after transfer. These mice succumbed within two months after transplantation and reproduced the original lethal disease ( Fig 7C) . Thymocytes from a diseased recipient animal were serially transplanted and killed secondary recipients within few weeks.
Discussion
In the present work, we have identified Hardy fraction B/C pro-B cells [15] which overlap with pre-B-I cells [2] as the origin of the B cell precursor malignancy (see Fig   S4 for an overview), which spontaneously developed in transgenic mice expressing a mutant, constitutively active Kit receptor (Kit D814Vflox+ Mx1-Cre + transgenic mice). We showed that the transformed cells transferred the disease to unconditioned recipients which rapidly succumbed to leukemia. In addition, we characterized the T cell precursor leukemia that a minority of mice developed.
Flow cytometric analysis revealed that the leukemic cells of all animals analyzed featured a remarkably uniform immuno-phenotype that suggested a pre-B-I cell [16] or pro-B cell origin [1] . The cells expressed common pro-B lymphocyte markers including CD24, CD43, CD93, CD117, CD127 and BP-1 [15, 22, 27] , whereas surface Ig expression as a hallmark of the B cell stage was absent [28] . Most childhood and adult B-ALL fall into the subgroup "common ALL" (BII according to the EGIL immuno-phenotypic classification [33] ) in which the leukemic cells express CD10 compatible with a pre-B-I cell [20] origin of the disease in human. A direct comparison between immuno-phenotypes of human and murine B lineage cells is difficult as CD10 and CD34 are not expressed during murine B cell development [34] and B220, CD25, CD117 and BP-1 are not expressed by human B cell progenitors [20] . However, close to 100% of common B-ALL clones carry rearranged
IgH loci but only a fraction additionally harbors IgL rearrangements [35] . Thus, the neoplastic B cells of our Kit D814V transgenic mice resemble human B-II ALL blasts.
Over the last two decades, the cancer stem cell concept emerged, which proposes a hierarchical organization of neoplasms equivalent to cellular homeostasis in normal tissues [24] . Rare self-renewing cancer stem cells give rise to more differentiated neoplastic cells with a finite life span, which account for most of the tumor mass, a concept that was also shown to be relevant in leukemic diseases, in particular AML [36] . In contrast, close to 100% of blastic B cells in human B-ALL seem to be capable of initiating the leukemia upon xenotransplantation [37, 38] . The leukemia of Kit D814V transgenic mice was successfully transplanted by transfer of low numbers of cells,
suggesting that most or all leukemic cells have the capacity to initiate the disease.
Therefore, a hierarchical organization of the malignant clone and the existence of a special subset of leukemia initiating cells seem unlikely [39] . Deregulated tyrosine kinase signaling was detected in human T cell acute lymphoblastic leukemia, but activating KIT mutations were not reported [41] . KIT is frequently expressed in early T cell precursor ALL, but this expression may reflect the immature cell origin rather than being linked to malignant transformation [42] . Kit D814V transgenic mice rarely developed a T cell ALL-like disease which may stem either from uncommitted lymphoid progenitors or from cells that were already committed to T cell development.
The leukemic B cells vigorously proliferated and infiltrated numerous organs
In man, the KIT D816V mutation causes systemic mastocytosis, which is accompanied by additional hematological non-mast cell lineage diseases in some cases [10] .
These additional hematological diseases are usually of myeloid origin. In such cases, the neoplastic mast cells and myeloid cells shared a common clonal origin and both harbored the activating KIT mutation [43] . There are infrequent reports of mastocytosis with additional lymphocytic neoplasia [44, 45] . However, the activating KIT mutation was usually not detected in cells of the accompanying lymphocytic disease [44] . In the few cases, in which KIT D816V was detected in B lymphocytes, the B cell compartment remained oligoclonal and did not exhibit signs of malignant M A N U S C R I P T
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16 transformation [46] . Our mice and a different Kit D814V+ mouse model [47] developed B lineage neoplasia with high frequency. This discrepancy between murine models and humans expressing activating KIT mutations might be explained by different signaling activity of murine versus human KIT receptor [48] .
However, there are important similarities of the B cell leukemia in our animals to human B-II ALL, including immuno-phenotype, partial rearrangement of Ig loci, developmental arrest close to the pre-BCR checkpoint and an incidence peak at young age. Moreover, deregulated signaling via the PI3K/AKT/mTOR [49] , MAPK [50] , and JAK/STAT [51] pathways is crucial for development of ALL. All of the latter pathways are activated by the Kit D814V mutation [52] and contributed in Kit In another mouse model of human leukemia, the Eµ-TCL1 transgenic mouse model for chronic lymphocytic leukemia (CLL) [54] , the precipitating mutation is not characteristic of the majority of human CLL. However, since the signaling pathways activated and additional oncogenic hits are very similar to the human disease, the model has proven its value in CLL research [55] . 
